Increasing Prevalence Of Cardiovascular Diseases Fueling The Growth Of The Market Due To Rising Risk Factors And Mortality Rates Is Supporting Development Across The Ticagrelor Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Market Value Of The Ticagrelor Market Projected To Expand During 2026–2030?

The ticagrelor market has experienced significant expansion in recent years. It is projected to grow from $1.93 billion in 2025 to $2.08 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.6%. Historically, this growth was driven by factors such as the limited availability of antiplatelet therapies, the increasing prevalence of cardiovascular disease, the expansion of hospital pharmacy networks, a rise in clinical trials for cardiovascular drugs, and growing awareness of heart attack and stroke risks.

The ticagrelor market is projected to experience robust expansion over the coming years, with its size forecast to reach $2.75 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. This projected growth during the forecast period is attributable to several factors, including the introduction of extended-release ticagrelor tablets, an expanded presence of retail and online pharmacy distribution channels, the increasing embrace of personalized cardiovascular treatment approaches, a rise in government-led efforts aimed at preventing cardiovascular diseases, and the integration of these treatments with digital health monitoring systems. Key trends anticipated during this period encompass the increasing application of ticagrelor in the management of acute coronary syndrome, a growing inclination towards oral antiplatelet therapies as opposed to injectable alternatives, the expansion of both hospital and ambulatory cardiology services, heightened public awareness surrounding the prevention of stroke and myocardial infarction, and the ongoing development of extended-release ticagrelor formulations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24726&type=smp

Which Significant Factors Are Encouraging Growth In The Ticagrelor Market?

The rising occurrence of cardiovascular ailments is projected to boost the expansion of the ticagrelor market in the future. These diseases encompass a range of conditions impacting the heart and circulatory system, specifically chronic ischemic heart disease, cardiac insufficiency, cerebrovascular accidents, and high blood pressure. The growing incidence of cardiovascular illnesses is mainly linked to unhealthy dietary habits, given that overconsumption of saturated fats, trans fats, added sugars, and sodium leads to hypertension, increased body weight, and heightened cholesterol, each being significant risk factors for heart ailments. Ticagrelor aids in managing cardiovascular diseases through inhibiting platelet aggregation, thereby decreasing the likelihood of blood clot formation. It enhances patient well-being by diminishing the probability of myocardial infarctions and strokes, particularly among vulnerable populations. As an illustration, in January 2024, data from the American Heart Association, a US-based non-profit entity, indicated that the age-adjusted mortality rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, marking a 4.0% rise from 224.4 per 100,000 in 2023. Consequently, the rising occurrence of cardiovascular ailments is fueling the expansion of the ticagrelor market.

Which Segment-Based Categories Are Covered In The Ticagrelor Market?

The ticagrelor market covered in this report is segmented –

1) By Type: 90 mg Tablet, 60 mg Tablet

2) By Drug Class: Antiplatelet Agents, Antithrombotic Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Acute Coronary Syndrome, Myocardial Infarction, Stroke Prevention, Other Applications

5) By End User: Hospitals And Clinics, Ambulatory Centers, Other End Users

Which Trends Are Contributing To Changes In The Ticagrelor Market?

Leading companies in the ticagrelor market are concentrating on securing regulatory clearances to broaden product applications, enhance market entry, and solidify their competitive stance. These regulatory approvals signify the official permission granted by governmental authorities to commercialize and distribute a product, ensuring it conforms to safety, efficacy, and quality standards. For example, in May 2025, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, received an abbreviated new drug application (ANDA) from the US Food & Drug Administration (USFDA) for its generic ticagrelor tablets 90 mg and tentative approval for the 60 mg strength. These tablets are prescribed to diminish the likelihood of cardiovascular events and operate by inhibiting platelet aggregation, thereby preventing the formation of blood clots.

Who Are The Key Market Participants In The Ticagrelor Market?

Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.

Access The Complete Ticagrelor Market Report:

https://www.thebusinessresearchcompany.com/report/ticagrelor-global-market-report

Which Region Contributes The Most To The Ticagrelor Market?

North America was the largest region in the ticagrelor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ticagrelor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Ticagrelor Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24726&type=smp

Browse Through More Reports Similar to the Global Ticagrelor Market 2026, By The Business Research Company

Induced Pluripotent Stem Cell Market Report 2026

https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report

Cell Based Assays Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Stem Cell Market Report 2026

https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795